RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs -the effector molecules of RNA interference -has had an enormous impact on experimental biology. RNA interference technologies are currently the most widely utilized techniques in functional genomic studies. Furthermore, there is an intense research effort aimed at developing short interfering RNAs for therapeutic purposes. A number of proof-of-principle experiments have demonstrated the clinical potential of appropriately designed short interfering RNAs in various diseases including viral infections, cancer and neurodegenerative disorders. Already, in such a short time from their discovery, Acuity Pharmaceuticals (August 2004) and Sirna Therapeutics (September 2004) have filed Investigational New Drug applications with the US FDA to begin clinical trials with modified siRNA molecules in patients with age-related macular degeneration. This review will give a brief overview of the mechanism of RNA interference and applications of the pathway in experimental biology will be discussed. The article will focus on recent developments related to the use of RNA interference technologies in mammalian systems and on potential clinical applications of short interfering RNA-mediated RNA interference.
R
NA interference (RNAi) is an evolutionary conserved post-tanscriptional gene-silencing pathway that was first discovered in the nematode worm, Caenorhabditis elegans, in 1998. 1 The mechanism of RNAi essentially involves double-stranded RNA (dsRNA)-mediated degradation of target mRNA. The initial landmark study demonstrated that injection of dsRNAs -both sense and antisense strands -into C. elegans resulted in pronounced silencing of a gene that has a sequence complementary to that of the dsRNA. 1 The gene-silencing efficiency was much greater when dsRNAs were administered rather than when either the sense or antisense strands alone were used. 1 Additionally, the gene-silencing mechanism persisted in the first generation offspring of worms treated with dsRNAs. 1 Notably, the discovery of RNAi provided explanations for post-transcriptional gene-silencing phenomena, referred to as cosuppression and quelling, that had been observed previously in plants (petunias) 2, 3 and filamentous fungi (Neurospora crassa), [4] [5] [6] respectively. Similarly, the finding that the C. elegans par-1 gene could be inhibited by both an antisense RNA strand as well as the sense RNA strand (which was used as a negative control) could be easily explained in retrospect with the discovery of RNAi. 7 The mechanism of RNAi has been investigated by both biochemical and genetic approaches. It was revealed that 21-to 23-nucleotide short interfering RNAs (siRNAs) are the effector molecules of the pathway. siRNA staggered duplexes with 2-nucleotide overhangs at the 3 0 terminii are produced following ATP-dependent processive cleavage of long dsRNAs by the enzyme Dicer, a member of the RNase III family of ribonucleases. [8] [9] [10] The antisense strand of the siRNA is then incorporated into an RNAinduced silencing complex (RISC) and is used to target perfectly complementary mRNA species. RISC cleaves the target mRNA, 10 nucleotides from the 5 0 end of the incorporated siRNA strand. 8 An amplification step within the RNAi pathway, which requires the activity of an RNA-dependent RNA polymerase (RdRP), has been identified in some organisms. 11, 12 In this process, RdRP uses the antisense strand of the siRNA as a template to generate additional dsRNAs. In plants, this amplification step is responsible for widespread resistance to viral infections by allowing RNAi-induced gene silencing to spread throughout somatic cells by cell-to-cell transfer of dsRNAs. 13 Since genes encoding RdRP have not been found in vertebrates -including the nearly complete Drosophila and human genomes -it is unclear whether amplification occurs in these organisms.
RNAi is related to another gene-silencing mechanism that involves Dicer and a group of small RNA molecules, known as microRNAs (miRNAs), that are expressed endogenously. Although genes in the host genome encode them, miRNAs are not involved in the pathway that leads to the production of a protein; instead they regulate the expression of mRNAs. Dicer produces the 21-to 22-nucleotide long, single-stranded miRNA molecules following cleavage of 70-nucleotide short hairpin precursors. 14 The miRNAs are then incorporated into an miRNA protein complex (miRNP). The miRNP complex associates with ribosomes and inhibits the translation of mRNAs that contain partially complementary sequences to the miRNAs in their 3 0 untranslated region. [15] [16] [17] [18] Recent findings suggest that if the target mRNA is perfectly complementary, miRNA molecules act in a way similar to siRNAs and induce the cleavage of the target mRNA. 19 The first miRNA molecules, lin-4 and let-7, which are involved in the regulation of cell differentiation and tissue development, were discovered in C. elegans.
20 Subsequently, many more have been identified in all multicellular organisms investigated including fruit flies, plants and humans. 21, 22 The function of most (particularly human) miRNAs is not yet known and there is intense interest in further characterizing the targets and mechanism of the action of miRNAs.
Similarly, the biological significance of RNAi has not yet been elucidated fully. It has been proposed that posttranscriptional gene-silencing pathways, including RNAi, evolved as defence mechanisms against RNA viruses and transposons even before plant and animals diverged. 4, 22 Indeed, it has been shown in plants 23 and Drosophila
24
cells that RNAi is the basis for protection from viral infection. Additionally, experiments in C. elegans indicating that genetic elements like transposons may be the targets of RNAi suggest that the RNAi is required for the maintenance of genomic integrity. 24, 25 Furthermore, the RNAi machinery has an important role in regulation of gene transcription by chromatin remodeling. The precise mechanisms of RNAi-mediated epigenetic gene silencing are not fully understood; however, recent studies in plants and fission yeast have provided some insights. 26 In short, it has been suggested that the pathway ultimately results in widespread gene silencing by the recruitment of enzymes that methylate the core histone, H3 which in turn leads to the recruitment of other proteins that are required to spread the silenced form of chromatin. 13, 26 In plants, it has been observed that in the transcriptionally repressed state of chromatin, siRNA-mediated DNA methylation may also occur. 13 Given its reliability and ease of use, RNAi has become the most widely used technique in functional genomic studies in several model organisms. Initially, long dsRNAs were used to transiently silence gene expression in plants, C. elegans and Drosophila to investigate the effects of loss of function of specific genes on phenotype. Systematic RNAi-based genetic screens performed in C. elegans [27] [28] [29] [30] [31] and Drosophila 32-34 highlight the usefulness of RNAi technology in functional genomics. Thus far, these screens identified have been involved in numerous fundamental processes including cell division, apoptosis and fat regulation pathways and it is anticipated that this type of genetic screen will continue to be widely used.
A nonspecific gene silencing mechanism initially hindered applications of dsRNA-induced RNAi in mammalian systems. It was found that transfecting mammalian cells with long dsRNAs (430 nucleotides) induces the antiviral interferon response resulting in global gene silencing and in certain cases cell death. 9, 35 The elucidation of the structure of siRNAs and the finding that chemically synthesized siRNA molecules can efficiently silence gene expression in mammalian cells has resulted in the widespread use of RNAi in mammalian cells. [36] [37] [38] Enormous amounts of information from functional genomic studies are becoming available literally on a daily basis, and the therapeutic potential of siRNAs is currently the subject of intense research. The following sections of this article will give an overview of the use of siRNA-mediated RNAi technologies in mammalian systems and recent developments related to potential clinical applications of siRNA molecules will be discussed.
Short RNA-mediated RNAi in mammalian cells
Genetic and biochemical analyses of the mechanisms of RNAi in a variety of organisms were crucial to solving the problem of the sequence-independent antiviral pathway resulting from the use of exogenous long dsRNAs. These approaches revealed conserved cellular components that are involved in the degradation of long dsRNAs into duplexes of 21-to 28-nucleotide siRNAs. Subsequently, the structure of siRNAs was elucidated and in a landmark study it was shown that transfection of mammalian cells with chemically synthesized 21-nucleotide siRNA molecules could result in sequence-specific target gene silencing via the RNAi pathway. 26 It is noteworthy that initially it was thought that siRNAs mediate RNAi without inducing of the interferon response; however, recent findings have brought this into question. 36, 39, 40 Following the initial report of siRNA structure and function, sequencespecific gene-silencing by siRNA-mediated RNAi became widely accepted as a powerful genetic tool in mammalian cells in a remarkably short period of time.
Studies have revealed that siRNAs are more stable in mammalian cells and physiological fluids than antisense oligodeoxyribonucleic acids (ODNs) and ribozymes, which have been extensively investigated nucleic acidbased molecules in earlier sequence-specific gene-silencing technologies. 41 Nevertheless, the gene-silencing effect of siRNAs is transient (transfected siRNAs are typically effective for about 3-7 days before they are naturally degraded), and is largely dependent on the rate of cell division. 9, 42 This is due to the fact that unlike C. elegans and plants, mammalian cells do not have systems to amplify and propagate RNAi. Therefore, there have been attempts to prolong the gene-silencing activity of siRNAs by introducing various chemical modifications that aim to increase the stability of the molecules while maintaining their gene-silencing potency. 9, 43, 44 It is noteworthy that phosphorothioate modifications (replacement of one of the nonbridging oxygen atoms in the phosphodiester bond by sulfur), similar to those introduced in ODNs that are currently in clinical trials, appear to be compatible with siRNAs. 9, 43 Another potential problem associated with the use of chemically synthesized siRNAs is related to the efficiency of delivery of the molecules into mammalian cells. A widely used approach to deliver sufficient quantities of siRNAs into mammalian cells involves encapsulating the negatively charged molecules into cationic liposomes or polymers that are taken up into cells. However, various cellsparticularly nondividing primary cells -are not transfectable using this method. 42, 45 Another approach employs electroporation. It has been identified that in certain cases the physiology of the cell may be altered by the use of these transfection procedures. 45 Despite these stability and delivery challenges, the transfection of chemically synthesized siRNAs is currently the most convenient method for investigating the immediate effects of inhibiting specific genes in mammalian cell cultures by RNAi.
Although the use of transfected siRNAs is appropriate in cases where transient gene silencing is sufficient, such as for many high-throughput cell-based gene-screening assays, it is not suitable in cases where prolonged inhibition of gene expression is necessary. For example, for many therapeutic applications long-term biological effects are required and the use of chemically synthesized siRNAs would be limited by the need for multiple or continuous administration of the interfering molecules. 46, 47 Similarly, siRNAs are not preferable for analysis of lossof-function phenotypes that develop over longer periods of time. 48, 49 Therefore, methods have been developed, which enable the use of expression vectors that produce short RNAs continuously in mammalian cells. [49] [50] [51] [52] [53] [54] [55] Such expression systems are based on plasmids or viral (adenoviral or lentiviral) vectors that encode the short RNA sequence. The DNA is transcribed and the transcript is processed into functional short RNA in the cells. A preferred method is to engineer vectors to express short hairpin -essentially double-stranded folded stemlooped -RNAs (shRNAs). 49, [52] [53] [54] [55] In many of these vectors the shRNA sequence is encoded between a polymerase (pol) III promoter and a thymidine transcription termination site. Following transcription, a stemloop structure is produced, which is subsequently processed inside the cell, converting the shRNA into approximately 21-nucleotide long RNA molecules that can induce RNAi. 49, [52] [53] [54] [55] A variation of this method involves the use of vectors in which separate pol III promoters initiate expression of the sense and antisense short RNA strands. 51 Plasmid and viral expression vectors have been used very successfully to transiently or stably transfect mammalian cells and short RNAmediated gene silencing has been observed for prolonged periods (several weeks) using these vehicles. Unlike plasmids, viral vectors have the advantage of delivering siRNAs to nondividing cells such as neurons and they are the most commonly used carriers for gene transfer because of their high in vitro transfection efficiency. 42 An advantage of lentiviral vectors in comparison to adenovirus is that they allow introduction of short RNAs into blood and bone marrow cells. 42 Although expression vectors are widely used to induce short RNA-mediated RNAi in cell culture and in vivo, it is anticipated that the toxicity of viral vectors will deter their use in humans. 42, 45 The safety concerns associated with the use of viral expression vectors in humans have been highlighted by the report of the death of a cancer patient who had received adenovirus. 56 Much research is currently focused at improving expression vectors to diminish the side effects and to enhance the delivery of siRNAs into specific target tissues using these vehicles.
Since the development of chemically synthesized siRNAs and short RNA producing expression vectors, RNAi is the most widely used pathway for loss-offunction phenotype analyses in mammalian cells and as mentioned above, enormous amounts of information relating to gene function are being continuously generated using this approach. It is widely accepted that given the success in analyzing single genes using RNAi methodologies, this technology will be applied on a large scale for genome-wide analyses. 45 This is of particular importance given the recent completion of the human, mouse and rat genomes, which have generated enormous amounts of sequence data that require interpretation into functional definitions. Small-scale efforts have identified that genome-wide siRNA libraries can be prepared by various methods including chemical synthesis or enzymatic digestion of long dsRNAs. 45, 57 Similarly, small-scale proof-of-principle experiments indicated that libraries can be produced by constructing shRNA expression vectors that target each gene. 45, 58 Recently, two groups have prepared resources for large-scale RNAi-based screens in mammals. 59, 60 In those studies, sets of arrayed expression libraries from chemically synthesized oligonucleotides which target 7914 and 9610 different human genes, respectively, were produced. 59, 60 Other approaches for large-scale genome-wide screening using RNAi, which involve generating a library of polymerase chain reaction products that encode shRNAs 61 and constructing random shRNA libraries based on manipulation of complementary or genomic DNA, [62] [63] [64] have also been reported recently. RNAi using genome-wide libraries is expected to complement current experiments that aim to functionally map the mouse genome by chemical or insertional mutagenesis. Furthermore, RNAi has the advantage that it can be extended to animals where generation of recombinant animals using embryonic stem cells is not possible. 45 It is anticipated that the design of large-scale libraries will evolve with advances in our understanding of the RNAi pathway, and protocols will eventually be established that will allow not only large-scale screens in cultured cells but also more complex procedures in whole animals. 45 
In vivo delivery of short RNAs
In addition to mammalian cell culture systems, short RNA-mediated RNAi technologies have been applied successfully in vivo. The initial demonstration of RNAi in vivo involved hydrodynamic tail vein injection of siRNAs into mice. 65 This method of siRNA delivery resulted in robust silencing of luciferase gene expression. 65 Similarly, high-pressure tail vein injections of siRNAs or plasmid encoding shRNA were used in subsequent studies in adult and postnatal mice. [66] [67] [68] [69] [70] Reductions in target gene expression of up to 90% were achieved in the liver and significant reductions were observed in the lung, kidney, spleen and pancreas. [66] [67] [68] [69] [70] The high potency of RNAi in the mouse liver prompted investigation of the therapeutic potential of siRNAs in a wide range of liver diseases. For example, endogenous genes encoding the FAS cell death receptor 71 and caspase 8, 72 that are involved in apoptosis pathways in hepatic injury that is triggered by viruses or rejection of transplants, have been targeted in models of acute liver failure. It was found that pretreatment with siRNAs targeting the FAS and caspase 8 genes protected the animals from acute liver failure induced by various agents. Similarly, treatment with the same siRNAs following administration of apoptotic inducing agents protected the animals from liver injury. Importantly, it was found that expression of FAS was inhibited for up to 10 days in mouse hepatocytes, indicating that siRNAs are stable and not rapidly diluted in vivo.
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Although the high-pressure tail vein injection technique is useful for proof-of-principle experiments in mice, it is a harsh method that is obviously limited and could not be translated to therapy of human diseases. Therefore, alternative delivery methods, predominantly those utilizing viral vectors that had been developed for earlier gene therapy technologies, have been applied for short RNAs. The potency of both adenoviral and retroviral carriers has been investigated. [72] [73] [74] [75] It should be noted that as mentioned above, the application of viral vectors in human therapy is also questionable and research is currently aimed at alleviating concerns related to the toxicity and tissue specificity of these expression vehicles. Nevertheless, one particular study that involved the use of a retrovirus that produces short RNAs targeting the carcinogenic K-ras allele in human pancreatic cancer cells has highlighted the exquisite specificity of appropriately designed siRNAs. 72 The findings from this study indicated that inhibition of K-ras expression in pancreatic cancer cells abolished their ability to form tumors following subcutaneous transplantation into athymic nude mice. 72 Importantly, only the carcinogenic K-ras allele and not the wild-type K-ras allele -which differs by only a single base pair -was silenced. 72 
Potential clinical applications of short RNAs
Along with the development of siRNA-and shRNAbased technologies for functional genomic studies, a large research effort has been directed at developing potential short RNA therapeutics for conditions such as viral infections, cancer and neurodegenerative diseases. Research relating to potential therapeutic uses of short RNAs is largely driven by the specificity and potency of the molecules. 45, 76 It should be noted that recent reports have called the selectivity and potency of siRNAs into question; however, there is consensus that these potential problems can be overcome with careful design and selection of short RNA molecules and mRNA targets. 9, 45 It is generally accepted that the major obstacles to short RNA-mediated therapy are inefficient in vivo delivery and uncertainty about potential toxicity. 9, 45 The delivery issue is the same as the problem that has been encountered for many years with earlier antisense technologies such as ODNs. It is predominantly for this reason that approval for the first RNAi-based clinical trials has been sought for the treatment of ocular diseases such as age-related macular degeneration (AMD). In these cases, short RNAs can be applied topically in a similar fashion to the antisense ODN, fomivirsen (Vitravene; Isis Pharmaceuticals), which was approved in 1998 by the US Food and Drug Administration (FDA) for the treatment of retinitis induced by cytomegalovirus. 77 Attempts to deliver concentrations of siRNAs that are therapeutically functional in vivo involve the use of liposomal carriers and virus-based expression vectors. However, there is uncertainty as to whether exogenous delivery of short RNA molecules using liposomal systems will facilitate the uptake of sufficient amounts of the molecules into target tissues. 42, 46, 78, 79 Furthermore, liposomal and viral-vector-based methods are not cell-or tissue-specific and uptake of short RNAs into non-target tissues may create problems. 46 In addition, there are toxicity issues associated with the use of viral-vector systems, as discussed above. Hence, there is an intense research effort aimed at improving the propertiesparticularly the cell-or tissue-specificity -of carriers for in vivo delivery of short RNAs.
There is some evidence indicating that vehicles targeting specific cell-surface receptors may be feasible carriers for in vivo delivery of siRNAs. For example, in one study an expression plasmid encoding an shRNA targeting human epidermal growth factor receptor mRNA was encapsulated in a liposome, which was conjugated to two receptor-specific monoclonal antibodies (Ab) that recognize the human insulin receptor (hIR) and the mouse transferrin receptor (mTfR). 80 In that study, the aim was to target human gliomas that were implanted in the brain of mice. The rationale was to utilize receptor-mediated transcytosis to cross the blood-brain barrier via binding of the mTf-Ab to the TfR, and to utilize receptormediated endocytosis to deliver the plasmid expression vector within the cancer cells via binding of the hIR-Ab to hIR, and subsequent internalization of the antibodyliposome-plasmid expression vector complex. 80 The findings indicated an 88% increase in survival time of mice with intracranial brain cancer that had been treated with weekly intravenous injections of the immunoliposomebased RNAi-mediating complex compared to control saline-treated mice. 80 Similarly, a more recent study has reported the use of siRNA containing nanoparticles that were prepared with polyethyleneimine and polyethylene glycol-Arg-Gly-Asp peptide conjugates. 82 The exposed Arg-Gly-Asp peptide ligands were used to target integrin expression, which is upregulated at sites of neovasculature. The nanoparticle polyplexes were used to deliver siRNAs that silence vascular endothelial growth factor (VEGF) receptor-2 expression and thereby tumor angiogenesis, specifically to tumor tissue. The findings indicated that intravenous administration of the stabilized nanoparticles into tumor-bearing mice resulted in selective uptake of the siRNAs into tumor tissue, RNAimediated inhibition of protein expression and inhibition of tumor angiogenesis and growth. 81 Importantly, the results suggested that the two levels of targetingselective delivery to tumors via the peptide ligand component and specific gene inhibition via the siRNA molecules -were successfully achieved using this strategy. 81 In other proof-of-principle studies modified siRNAs conjugated to cholesterol via a pyrrolidine linker have been administered to mice to specifically silence the apolipoprotein B gene, which is involved in coronary artery disease, to provide evidence that chemical conjugation strategies can be successfully applied to achieve systemic activity in vivo. 82 Collectively, these studies highlight methods that can potentially be adapted to improve the properties of in vivo delivery systems for short RNA molecules.
Despite the problems associated with the delivery of short RNAs in humans, a wide variety of disease-related genes have been targeted with siRNAs and shRNAs in cell culture and animal model systems. Numerous studies have been carried out to investigate the potential of RNAi therapies against viral hepatitis, which as discussed above is an attractive target given the potency of short RNAs in the liver. 70, 71, 83 Important proof-of-principle experiments have demonstrated that siRNAs can protect mice from liver diseases including fulminant hepatitis infection. 70, 71 Additionally, RNAi-based therapies have been investigated for the treatment of human immunodeficiency virus (HIV) infection. Several early and late HIV-encoded RNAs including the TAR element, 84 89 Proof-of-principle experiments have also marked the therapeutic potential of short RNAs against a major class of neurodegenerative disorders, such as Huntington's disease, which are induced by polyglutamine toxicity. 75, 90 Other studies have highlighted the potential of RNAi technologies for the treatment of cancer. 46, 47, [91] [92] [93] There is particular interest in targeting genes such Bcl-2 and p53 that are involved in apoptotic pathways, 46, 47, 94, 95 as well as in silencing VEGF expression, which is involved in tumor angiogenesis. 46, [96] [97] [98] The use of short RNA-mediated RNAi to target genes expressing oncogenic fusion proteins, such as the Bcr-Abl oncoprotein p210 that is found in chronic myelogenous leukemia, has also generated interest. 99, 100 With respect to cancer, the potential use of short RNAs in combination with conventional therapies such chemotherapy or radiotherapy -either to complement or to augment the treatment modalities -has been proposed. 46, 47 For example, it is well known that approximately one-third of patients acquire resistance to chemotherapeutic agents. 101 This phenomenon has been termed multidrug resistance (MDR) and in many cases is the result of overexpression of the MDR1 gene, which encodes P-glycoprotein (PGP), a member of the superfamily of ABC transporters. 102, 103 Although chemosensitizers such as verapamil may be used to circumvent MDR by inhibiting the drug efflux activity of the PGP pump, they are limited by there toxicity at pharmacologically active doses. 102, 103 Therefore, RNAi technology offers an alternative method for restoring chemosensitivity in drugresistant cancer cells. Experiments have been conducted in cell culture systems and the findings have indicated successful modulation of the MDR phenotype using RNAi in various cell lines. [104] [105] [106] [107] Additionally, there is intense interest in the use of combinations of apoptosisinducing agents, for example tumor necrosis factorrelated apoptosis-inducing ligand, with siRNAs that silence genes which inhibit apoptosis such as Bcl-2, FLICE-like inhibitory protein or inhibition of apoptosis proteins. 108 Another approach that has been used to augment the effects of radiation and chemotherapy in cancer cells is RNAi-mediated silencing of DNA repair factors. 109 Short RNAs targeting the pivotal proteins, ataxia telangiectasia-mutated protein (ATM), ataxia telangiectasia-related (ATR) protein and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), in DNA damage signaling and repair pathways, have been used to enhance radiation and chemotherapy-mediated cell killing in human cancer cells. 109 These findings imply that short RNA molecules can potentially be developed for use as radio-or chemo-sensitizing agents.
RNAi technologies have progressed in such a rapid rate that already applications have been filed with the FDA for approval of clinical trials with siRNA molecules. Acuity Pharmaceuticals (www.acuitypharma.com) has filed the first Investigational New Drug (IND) application for therapeutic RNAi with the US FDA (August 2004). The company has developed an siRNA, Cand5, that will be used in clinical trials in patients with AMD. Cand5, is designed to inhibit the production of VEGF, which has a central role in the development of ocular neovascularization and vision loss in AMD and diabetic retinopathy. Similarly, Sirna Therapeutics (www.sirna.com) has announced (September 2004) the filing of an IND application with the FDA to begin clinical trials with a chemically modified siRNA, Sirna-027, also in patients with AMD. The Sirna-027 molecule to be used in the trials targets the VEGF receptor-1 and is designed to inhibit pathologic angiogenesis initiated by VEGF and placental growth factor. Approval for the first RNAi-based clinical trials has been sought for the treatment of ocular diseases such as AMD for two main reasons. First, the VEGF receptor is an appropriate disease-related target. This has been validated by experiments in mice, which showed that siRNAs targeting mouse VEGF blocked endogenous VEGF production and protected the animals from choroidal neovascularization which causes macular degeneration. 110 Second, as alluded to earlier, the problem of delivery of siRNAs is less significant since the molecules can be applied topically, thereby making it easier to achieve therapeutically relevant concentrations. These IND applications represent the first steps towards RNAi-based therapeutics.
Conclusion
The discovery of RNAi has had an enormous impact on experimental biology and in particular functional genomics. To date, siRNAs and shRNAs have been used extensively to investigate gene function in mammalian cell cultures and have been applied successfully in vivo. Furthermore, extensive siRNA and shRNA libraries for genome-wide screening have been produced. Undoubtedly, these types of high-throughput screens will have a very important role in decoding the enormous amount of sequence information that is available, especially for the mouse and human genomes. In addition to assigning biological functions to different genes using cell culture systems, it is anticipated that the RNAi pathway will ultimately be utilized to perform more complex genetic experiments in vivo.
Given the exquisite specificity -when designed appropriately -and potency of short RNAs, there is much excitement with respect to translation of RNAibased technology into the clinical for therapy of various diseases. Scenarios where short RNA-mediated RNAi can be applied either as a stand-alone therapeutic modality or as an adjunct to conventional therapies have been considered. However, there are some hurdles that need to be overcome before the therapeutic potential of short RNA molecules can be realized. The major concern is the challenge associated with efficient functional delivery of siRNAs in vivo. The specificity and potency of short RNAs is driving research into improving delivery methods and it is foreseeable that with accumulation of further knowledge, RNAi will have a prevalent role in the management of various human diseases.
